About Gemelli Biotech
Gemelli Biotech is a company based in Los Angeles (United States) founded in 2018 by Ali Rezaie, Kapil Gupta, Ruchi Mathur, Mark Pimentel, and Matt Mitcho.. Gemelli Biotech has raised $23.03 million across 3 funding rounds from investors including Cedars Sinai, Blue Ox Healthcare Partners and Carolina Angel Network. Gemelli Biotech offers products and services including Precision Diagnostics. Gemelli Biotech operates in a competitive market with competitors including Oxford MEStar, Chosen Diagnostics, AgPlus Diagnostics, Venaxis and ibs-smart, among others.
- Headquarter Los Angeles, United States
- Founders Ali Rezaie, Kapil Gupta, Ruchi Mathur, Mark Pimentel, Matt Mitcho
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Gemelli Biotech Corp.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$23.03 M (USD)
in 3 rounds
-
Latest Funding Round
$21.18 M (USD), Series A
Dec 07, 2021
-
Investors
Cedars Sinai
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Gemelli Biotech
Gemelli Biotech offers a comprehensive portfolio of products and services, including Precision Diagnostics. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Non-invasive tools for detecting biomarkers in GI diseases like SIBO.
Unlock access to complete
Funding Insights of Gemelli Biotech
Gemelli Biotech has successfully raised a total of $23.03M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $21.18 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series A — $21.2M
-
First Round
First Round
(27 Jun 2019)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2021 | Amount | Series A - Gemelli Biotech | Valuation | Blue Ox Healthcare Partners | |
| Mar, 2021 | Amount | Debt – Conventional - Gemelli Biotech | Valuation |
investors |
|
| Jun, 2019 | Amount | Seed - Gemelli Biotech | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Gemelli Biotech
Gemelli Biotech has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Cedars Sinai, Blue Ox Healthcare Partners and Carolina Angel Network. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Commercial-ready healthcare innovators are targeted for private equity investments.
|
Founded Year | Domain | Location | |
|
Early-stage investment opportunities are facilitated for UNC-affiliated startups.
|
Founded Year | Domain | Location | |
|
Early-stage tech companies in Asia and the US are funded.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Gemelli Biotech
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Gemelli Biotech
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Gemelli Biotech Comparisons
Competitors of Gemelli Biotech
Gemelli Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Oxford MEStar, Chosen Diagnostics, AgPlus Diagnostics, Venaxis and ibs-smart, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of novel scaffolds for tissue engineering and stem cell delivery
|
|
| domain | founded_year | HQ Location |
Developing a novel MDx kit to diagnose a severe bowel disorder in premature infants
|
|
| domain | founded_year | HQ Location |
Portable diagnostic platforms are developed using electrochemistry and nanotechnology.
|
|
| domain | founded_year | HQ Location |
In vitro diagnostic tests for appendicitis are developed by Venaxis.
|
|
| domain | founded_year | HQ Location |
Develops and provides at-home blood tests for diagnosing irritable bowel syndrome.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Gemelli Biotech
Frequently Asked Questions about Gemelli Biotech
When was Gemelli Biotech founded?
Gemelli Biotech was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Where is Gemelli Biotech located?
Gemelli Biotech is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Who is the current CEO of Gemelli Biotech?
Matt Mitcho is the current CEO of Gemelli Biotech. They have also founded this company.
Is Gemelli Biotech a funded company?
Gemelli Biotech is a funded company, having raised a total of $23.03M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1.85M, raised on Jun 27, 2019.
What does Gemelli Biotech do?
Gemelli Biotech was founded in 2018 in Los Angeles, United States, within the biotechnology sector. Diagnostics and therapeutics focused on the human microbiome are developed, often in partnership with Cedars-Sinai Medical Center. Key products include ibs-smart, a blood test for irritable bowel syndrome variants, and sclero-smart, which assesses anti-vinculin antibody levels in systemic sclerosis and scleroderma patients. Further products remain in the pipeline for upcoming releases.
Who are the top competitors of Gemelli Biotech?
Gemelli Biotech's top competitors include Chosen Diagnostics, AgPlus Diagnostics and Oxford MEStar.
What products or services does Gemelli Biotech offer?
Gemelli Biotech offers Precision Diagnostics.
Who are Gemelli Biotech's investors?
Gemelli Biotech has 4 investors. Key investors include Cedars Sinai, Blue Ox Healthcare Partners, Carolina Angel Network, and CerraCap Ventures.